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What’s already known about this topic?33
 The evidence base for atopic eczema (AE) treatments is broad and limited by poor quality trials34
 The last systematic review to provide an overview of all published AE randomised controlled trials35
(RCTs) was conducted in 200036
37
What does this study add?38
 Over 500 RCTs have been published on treatments for AE, but many research gaps remain39
 This summary highlights treatment for which there is reasonable evidence of benefit, and those for40
which there is reasonable evidence of no benefit41
 Future research priorities that have no current RCT evidence include the role of allergy testing42
(followed by allergen avoidance), and modified bathing habits in the management of AE43
44
Evidence-base for atopic eczema treatments
2
Summary (Abstract)45
46
Atopic eczema (AE) is a common chronic inflammatory skin condition. Whilst many AE treatment options are47
available, the evidence to support their efficacy varies in depth and quality. In 2000, an NIHR HTA systematic48
review identified and evaluated existing randomised controlled trials (RCTs) of AE treatments. To ensure49
continuing utility, the NIHR commissioned an update to the review. Here, we present an overview of the50
updated report and key findings.51
52
Systematic reviews and RCTs of AE treatments that included participants with AE (criteria based or diagnosed)53
were identified using: MEDLINE, EMBASE, CENTRAL, LILACS, AMED, CINAHL and Cochrane Skin Group54
Specialised Register (searched to August 31st 2013 (RCTs) and 31st December 2015 (systematic reviews)).55
Outcome measures included: symptoms, AE severity, quality-of-life, and adverse effects. Study quality was56
assessed using the Cochrane Collaboration risk of bias tool.57
58
Of the 287 new RCTs identified, only 22 (8%) were judged to be low risk of bias. When combined with RCTs59
from the previous review (n= 254), we found ‘reasonable evidence of benefit’ for corticosteroids, calcineurin60
inhibitors, AtopiclairTM, ciclosporin, azathioprine, ultraviolet light and education programmes.61
Interventions with reasonable evidence of ’‘no benefit’ included some dietary interventions, ion exchange62
water softeners, multiple daily applications of topical corticosteroids and antibiotic-containing corticosteroids63
for non-infected AE. Many common treatments lack evidence of efficacy and warrant further evaluation.64
65
The evidence base for AE is still hampered by poor trial design and reporting. The trials included in this review66
were used to establish the Global Resource of Eczema Trials (GREAT) Database.67
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Introduction68
Atopic eczema (AE) (syn. atopic dermatitis), is a chronic inflammatory skin condition characterised by an itchy69
red rash that affects all age groups1. AE has one of the highest burdens compared to other skin diseases.270
71
The evidence-base for AE treatments is extensive, but has limitations in terms of quality and relevance.3 This is72
exemplified by the 'Systematic Review of Treatments for Atopic Eczema', published by the National Institute73
for Health Research (NIHR), which identified 254 RCTs of AE treatment covering 47 interventions.4 The74
encompassing nature of the review, and critical appraisal of the evidence therein, has helped to inform clinical75
guidelines on an international level for over a decade and the report has been heavily cited, with more than76
650 citations listed in Google Scholar at time of writing.5-877
78
To ensure its continuing utility, the NIHR commissioned an update of the systematic scoping review as part of79
a programme of work on the prevention and treatment of skin disease,9 with the aim of summarising the80
evidence-base for AE treatments for guideline writers, healthcare professionals and patients. This review will81
also help in identifying research gaps to be addressed in the future, and in identifying topics suitable for82
specific targeted systematic reviews.83
84
The current paper provides a summary of the updated scoping review (which is freely available through the85
NIHR Journal series)9, with a specific focus on the overall findings and conclusions.86
87
88
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Methods used for the scoping review89
The following section briefly described the methodology employed to create the scoping review, which can be90
viewed in its entirety in the methods section of the full report. 991
Design92
This was a systematic scoping review of all systematic reviews and randomised controlled trials (RCTs) for AE93
treatments. A scoping review attempts to systematically map existing evidence on a given topic and identify94
potential gaps in the literature to inform future research priorities. It differs from a clinically-focussed95
systematic review in that it often covers a much broader topic area, summarises the evidence in a qualitative96
format and offers limited critical appraisal.1097
Type of studies included98
As systematic reviews and RCTs represent the best source of unbiased evidence on the effectiveness of99
treatments, we only included these types of studies. Studies were required to contain at least one clinical100
outcome. Prevention studies, provocation studies, changes in blood biochemistry and evaluations of cellular101
mechanisms were excluded.102
Participants103
Studies were included if participants (of any age) had AE, as diagnosed by a physician, or that met with a104
diagnostic criteria (e.g. Hanifin and Rajka,11 UK working party12 or similar).105
Main outcome measures106
Outcome measures chosen for the review were deliberately broad, in order to reflect those commonly used in107
AE trials.13,14 Changes in patient-rated symptoms such as itching (pruritus) or sleep loss were extracted where108
possible. Global severity, as rated by patients or their physician, was also sought. Other outcomes included109
changes in AE severity rating scales; quality of life; and adverse events (encompassing adverse events and110
adverse reactions depending on how these were reported in the original RCTs).111
Search strategy112
We searched the following electronic databases (search dates end of 1999 to 31st August 2013) - MEDLINE;113
EMBASE; CENTRAL; The Cochrane Skin Group Specialised Trials Register; Latin American and Caribbean Health114
Sciences database (LILACS); Allied and Complementary Medicine Database (AMED); Cumulative Index to115
Nursing and Allied Health Literature (CINAHL) (Supplementary Figure 1). We also searched www.controlled-116
trials.com for completed and ongoing RCTs using the terms atopic dermatitis, atopic eczema and eczema as117
well as using our extensive contacts in the field of AE research to identify other ongoing studies.118
119
Systematic reviews on AE treatments were searched for up until Dec 2015 using PubMed, EMBASE, the120
Cochrane Library and NHS Evidence. Where appropriate the results of these specific systematic reviews are121
presented alongside the RCT evidence.122
123
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We used the following disease terms for AE: atopic dermatitis, atopic eczema, eczema, neurodermatitis,124
infantile eczema, childhood eczema, or Besniers’ prurigo. No language restrictions were applied; data from125
non-English papers was extracted by international colleagues. References were screened by one author (either126
SS or HN), with discussion with a second author as required (HW, KT or SB). Those studies using terms that127
were definitely not AE, such as allergic contact eczema, were excluded. Terms that were considered possibly128
AE, such as ‘childhood eczema’, were scrutinised and only included if the description of the participants clearly129
indicated AE.130
Data assessment and study quality131
Data was independently extracted by two authors (HN and SB or SS) with discrepancies resolved by consensus132
or by an arbitrator (HCW, KST or FMD). Although primarily a scoping review, trial quality (specifically133
randomisation, allocation concealment and blinding) was evaluated. This was done using Cochrane134
collaboration’s risk of bias assessment tool.15 The overall risk of bias for the included studies was summarised135
according to defined criteria (Supplementary Table 1). Authors were not blinded to the identity of the RCT136
authors, and a more detailed quality assessment (such as GRADE16) was unfeasible given the number of137
included studies.138
Presentation of the results139
Results are presented according to broad categories of treatments: i) topical corticosteroids and topical140
immunomodulators; ii) emollients and other topical treatments (including bath additives and oils ); iii)141
antimicrobials including antibiotics, antiseptics and antifungals; iv) antihistamines and mast cell stabilisers; v)142
dietary interventions (including probiotics, essential fatty acids, vitamins, cows’ milk substitutes); vi ) non-143
pharmacological interventions (including education, psychological therapies, different ways of providing AE144
care, allergen avoidance followed by allergen avoidance or re-introduction and medical devices); vi)145
phototherapy; vii) systemic immunomodulatory agents; viii) complementary therapies (homeopathy,146
aromatherapy, hypnotherapy, Chinese herbal medicine, St John’s Wort, acupuncture, balneotherapy,147
relaxation); ix) other.148
149
For clarity of interpretation, results are also summarised according to categories of evidence:150
i) treatments for which there is reasonable evidence of benefit151
ii) treatments for which there is reasonable evidence of no-clinically useful benefit152
iii) treatments for which there is insufficient evidence to inform clinical decision-making153
iv) treatments with an absence of RCT evidence.154
155
Classification of treatment options into these four categories was a qualitative judgement on the part of the156
authors based on availability and quality of the evidence, and the likelihood of clinically important effects. It is157
not intended to signify that all uncertainty has been resolved in those areas classed as having reasonable158
evidence of benefit or reasonable evidence of no benefit – simply that there is a reasonable body of evidence159
that may usefully inform clinical decision-making. In this paper, we have not tried to summarise the possible160
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harms of all included studies, but harms and drawbacks of treatments are included for all treatment categories161
in the main report.162
163
Pooling of the trial results using meta-analysis was not possible due to the very wide nature of interventions164
included, and the very heterogeneous nature of study participants and outcomes. However, interventions with165
evidence of benefit or evidence of no benefit have been mapped to the latest relevant systematic reviews on166
these topics where they exist.167
Results of the review168
Summary of trials169
In addition to the 254 RCTs identified in the original 2000 scoping review, this updated includes an additional170
287 new RCTs, making 541 RCTs in total covering 92 different interventions for treating AE. The number of171
RCTs published according to broad treatment categories is shown (Figure 1), with further details provided in172
Supplementary Figure 2.173
174
The size of the newly identified RCTs varied widely from seven randomised participants to 972175
participants. Most of the trials were conducted in secondary care, and tended to include participants176
with either moderate to severe disease, or mild to moderate disease. Very few RCTs included all177
severities of AE.178
Reporting was generally poor, with “unclear” categories dominating the assessments: randomisation method179
(2% high, 36% low and 62% unclear risk of bias), allocation concealment (3% high, 15% low and 82% unclear180
risk of bias), and blinding or masking of the intervention (15% high, 28% low, 57% unclear risk of bias). Only181
22/287 (8%) were considered to be at low risk of bias for all three quality criteria (randomisation, allocation182
concealment and blinding). Overall agreement between the team members on the availability and quality of183
the evidence, and the likelihood of clinically important effects was good.184
185
186
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188
Figure 1: Number of included RCTs per treatment category189
190
191
Treatments with reasonable evidence of benefit192
Fourteen interventions or treatment approaches were felt to have reasonable evidence of benefit (Table 1).193
These include the use of topical corticosteroids and topical calcineurin inhibitors, both for the treatment of194
active AE, and as intermittent proactive (maintenance) therapy for the prevention of AE flares. Other195
interventions including AtopiclairTM emollient, ultraviolet light therapy, azathioprine and ciclosporin, all had196
reasonable evidence of benefit compared to placebo/vehicle. Similarly, RCT and systematic review evidence197
suggested that education may be beneficial, although the exact components of a successful education198
programme in different clinical settings is still unclear.199
200
Of the 14 interventions with reasonable evidence of benefit, 10/14 (71%) have been the subject of more201
detailed, treatment-specific systematic reviews (Table 1).202
Treatments with evidence of no clinically useful benefit203
Nine interventions were deemed to have a reasonable level of evidence of no benefit in treating AE (Table 2):204
topical corticosteroids containing an antibiotic for the treatment of AE that is not infected; Mycobacterium205
vaccae vaccine; probiotics; ion exchange water softeners; evening primrose oil and borage oil.206
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Treatments which require more research207
There are many treatments for AE that have insufficient or contradictory RCT evidence, for which further208
research is required (Table 3). Some of the treatments have been trialled many times, however, the quality of209
reporting means that evidence for these treatments is not yet strong enough.210
Treatments with an absence of RCT evidence211
The scoping review has helped to identify areas for which there is currently no RCT evidence for commonly212
used practices for the treatment of AE including: dilution of topical corticosteroids, order of application of213
topical corticosteroids and emollients, impregnated bandages (zinc or ichthammol paste bandages), modified214
bathing habits (non-antiseptic bath additives, soap avoidance, frequency of bathing), and the role of routine215
allergy testing followed by allergen avoidance or re-introduction.216
217
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Discussion218
Main findings219
The systematic scoping review findings indicated there were only a small number of treatments with evidence220
of benefit (Table 1) and some treatments with evidence of no benefit (Table 2). For the majority of treatments,221
however, further but better designed research is needed (see Table 3). It is disappointing that there was a lack222
of strong evidence base for some of the most widely used AE treatments, such as emollients and bandages.223
However, stopping or restricting the use of these treatments on the basis of lack of RCT evidence would not224
benefit patients. Although information on treatment drawbacks and harms are included for each intervention225
in the main review, we have not tried to summarise them in this report due to their diverse and treatment-226
specific nature. Generally, harms were reported less well than treatment benefits resulting in an asymmetry of227
information to inform patient choices.228
In addition to the established approach for treating AE flares with topical corticosteroids, perhaps the single229
largest advance in AE treatment since the 2000 review has been the strong evidence supporting the value of a230
proactive approach for maintaining AE remission through the use of twice weekly topical corticosteroids or231
calcineurin inhibitors.17 Educational approaches have also emerged as a potentially promising intervention,232
although further work is needed to establish the most important components of the intervention, and the233
most cost-effective ways of delivering education in different health settings.234
The finding that AtopiclairTM emollient has emerged as a potentially useful intervention for AE in four out of235
five industry-sponsored trials is difficult to interpret at this time. High-quality, independent trials are now236
needed that compare AtopiclairTM to other commonly used (and cheaper) emollients.237
The understanding that some interventions now have sufficient evidence to suggest little or no benefit for AE238
patients is equally important. These interventions provide options for disinvestment, ensuring that available239
funds are channelled to the most effective treatments. Possible areas to consider for disinvestment include:240
the application of topical corticosteroids twice a day, as once-daily application has been shown to be equally241
effective; topical corticosteroids containing antibiotics when used for the management of non-infected AE; use242
of ion exchange water softeners; and dietary supplements (probiotics, borage oil, evening primrose oil).243
Implications for research244
There is a lack of AE treatment trials conducted in a primary care setting, where most patients are seen. The245
research questions being investigated often fail to reflect the most pressing questions for clinicians and246
patients. A recent James Lind Alliance Priority Setting Partnership 3 identified the most important treatment247
uncertainties as judged by patients and clinicians. When set in the context of the updated evidence base from248
the review, the following areas identified from the Priority Setting Partnership seem to be most pressing:249
250
Priority areas with no current RCT evidence251
 What role might allergy tests play in treating AE?252
 What is the best way for people with AE to wash?253
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 Which should be applied first when treating AE – emollients or topical corticosteroids?254
255
Priority areas with limited RCT evidence256
 What is the best and safest way of using topical corticosteroids for AE?257
 What is the long-term safety of applying topical steroids to the skin for AE?258
 Which emollient is the most effective and safe in treating AE?259
 What is the best psychological treatment for itching/scratching in AE?260
 What are the best and safest 'natural' products to apply to the skin?261
 How much does avoidance of irritants and allergens help people with AE?262
 What is the role of diet in treating AE (exclusion diets and nutritional supplements)263
 Which is more effective in the management of AE: education programmes, GP care, nurse-led care, dermatology-led264
care of multi-disciplinary teams?265
 Which is safer and more effective in treating AE: topical corticosteroids or calcineurin inhibitors (especially for266
proactive flare prevention)?267
 How effective are interventions to reduce skin infections in the management of AE?268
 What is the best and safest way of using drugs that suppress the immune system (particularly in children)269
270
Some important topics have already been picked up by NIHR funding bodies, and large pragmatic trials are271
currently underway in the UK evaluating the role of topical and oral antibiotics for the treatment of infected272
AE (CREAM) (UKCRN ID 11233), silk clothing for the management of moderate to severe AE (CLOTHES) (UKCRN273
ID 15132), the role of bath emollients in the management of AE (BATHE: UKCRN ID 17348) and a feasibility trial274
of emollient clinical and cost effectiveness (COMET: UKCRN ID 16571).275
Methodological research276
One of the most pressing concerns identified by this review is the continued preponderance of small, poorly277
reported and poorly conducted trials. Greater efforts to work collaboratively to conduct large, well designed278
studies that address important questions, can only be of benefit to patients and healthcare providers.279
280
Similarly, the ability to combine study results in meta-analysis continues to be hampered by the wide variation281
in outcome measures used. The move towards using the same core outcome sets as encouraged by the282
Harmonising Outcome Measures for Eczema (HOME) initiative18-20 (www.homeforeczema.org) are likely to be283
beneficial for future clinical interpretation and evidence syntheses.284
Strengths and limitations of the review285
The updated review has used a clear methodology for identifying RCTs for inclusion, which has minimised286
potential selection bias. However, despite searching the main bibliographic databases (MEDLINE and EMBASE)287
and several smaller, specialist databases (CINAHL, AMED and LILACS), it is possible that we might have missed288
some RCTs. Many of the treatments that are lacking in RCT evidence have nevertheless been studied using289
uncontrolled designs, which may provide additional useful information. Similarly, large cohort studies are290
required to detect rare treatment adverse effects.291
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292
Whilst masking the identity of the trial authors from the review team was not practical, this may have293
introduced bias when summarising qualitative aspects of the results. Given the very wide scope of the review294
and heterogeneous nature of participants, interventions and outcomes, it was not practical to undertake295
detailed meta-analysis for single interventions. These will need to be conducted (where appropriate) within296
much narrower intervention-specific systematic reviews in the future.297
298
Our classification of treatment options into categories such as “evidence of benefit to support” is not299
tantamount to a positive recommendation for widespread use or otherwise, as that is the remit of guideline300
developers and depends on factors such as magnitude of benefit, adverse effects, how the treatment301
compares with existing active treatments, availability, cost effectiveness and population most likely to benefit.302
303
As with all systematic reviews, the evidence presented will become out of date quite rapidly for some topics,304
and readers of the review are also directed to our free to access database of AE RCTs Global Resource of305
EczemA Trials (GREAT Database, accessible at http://www.greatdatabase.org.uk), which contains details of all306
the studies in the scoping review and can be used by readers who wish to investigate particular included or307
excluded studies further.308
Conclusion309
The number of RCTs for AE has increased substantially since the year 20004 yet most are still small, poorly310
reported, and do not address questions of clinical importance to patients and healthcare professionals311
We hope that our work provides an easily accessible guide for patients and clinicians wishing to research312
treatment effects, and that it will be used by guideline developers to prevent duplication of effort in collating313
and evaluating the available evidence base for AE treatments. AE researchers will be able to identify potential314
research gaps and systematic reviews that require further work.315
316
317
318
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Table and figure legends319
Figure 1: Number of included RCTs per treatment category320
321
Table 1: Treatments with reasonable evidence of benefit for AE patients322
Table 2: Treatments with reasonable evidence of no benefit for AE patients323
Table 3: Treatments which require more research324
325
Supplementary Figure 1: Search strategy used to identify trials326
Supplementary Table 1: Criteria used for discussing the risk of bias in the summaries of treatment categories327
328
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Table 1: Treatments with reasonable evidence of benefit for AE patients329
* Please note, 3 studies were included within one paper330
331
Evidence of benefit: at least one good quality RCT or a large body of evidence and a clinically useful finding. We defined a ‘good quality’ trial as well designed
and well reported and with a magnitude of benefit deemed by the authors to be clinically relevant, and ‘large body of evidence’ as enough trials with
consistent evidence of clinically relevant benefit, despite some limitations in reporting
Intervention and severity of AE Population Trials(n)
Participants
(n)
Risk of
bias Systematic Review(s)
Topical Corticosteroids
Corticosteroids (various strengths) are superior to vehicle
for AE of all severities
Adults and
children 23
21-42 3857 Mostlyunclear None
Topical Calcineurin Inhibitors
Pimecrolimus (1%) is superior to vehicle for mild to
moderate AE
Mainly
children
1643-57 3149 Mostly
unclear
Chen (2011)58
Number of included studies: 6 (<18
years only)
Meta-analysis: OR 3.21, 95% CI
2.48 to 4.14
Tacrolimus (0.03, 0.1, 0.3%) is superior to vehicle for
moderate to severe AE
Adults and
children 9
59-65 2089 Mostlyunclear
Chen (2011)58
Number of included studies: 4 (<18
years only)
Meta-analysis: OR 4.56, 95% CI
2.80 to 7.44
Tacrolimus (0.03, 0.1%) is superior to hydrocortisone
acetate (1%) for moderate-to severe AE Children 2
66,67 1184 Unclear
Martins (2015)68
Number of included studies: 2
Tacrolimus 0.03%: RR 2.58, 95% CI
1.96 to 3.38
Number of included studies:1
Tacrolimus 1%: RR 3.09, 95% CI
2.14 to 4.45
Tacrolimus (0.1%) superior to fluticasone propionate
ointment (0.005%) for moderate to severe facial AE Adults 1
69 568 Mostlyunclear Not applicable
Tacrolimus (0.1, 0.03%) is superior to pimecrolimus (1%) for
AE of all severities
Adults and
children 5
70-72* 1243 Mostly low
Martins (2015)68
Number of included studies: 3
Meta-analysis: RR 1.80, 95% CI
1.35 to 2.42
Proactive (maintenance) topical therapy for preventing
flares
Corticosteroids applied twice a week are superior to vehicle
for moderate to severe AE
Adults and
children 4
73-76 929 Mostlyunclear
Schmitt (2011)17
Number of included studies: 4
Meta-analysis: RR 0.46, 95% CI
0.38-0.55
Tacrolimus (0.1, 0.03%) applied twice a week is superior to
vehicle for mild to severe AE
Adults and
children 4
77-80 741 Mostlyunclear
Schmitt (2011)17
Number of included studies: 3
Meta-analysis: RR 0.78, 95% CI
0.60-1.00
Pimecrolimus (1%) applied twice a week is superior to
vehicle for AE of all severities
Mainly
children 2
44,81 251 Mostly low None
Systemic Therapies
Ciclosporin superior to placebo for severe AE Adults 482-85 113 Mostlyunclear
Schmitt 200786
Number of included studies: 12
Meta-analysis: Included non-RCTs
Azathioprine superior to placebo for moderate to severe AE Adults 287,88 100 Mostly low
Schram 201189
Number of included studies: 2
Meta-analysis: not done
Ultra-violet Light Therapy
NB-UVB superior to placebo (visible light) for moderate to
severe AE Adults 2
90,91 116 Mostlyunclear
Dogra 201592
Number of included studies: 13
(included non-RCTs)
Meta-analysis: not done
Gambichler 200593
Number of included studies: 3
(included non-RCTs)
Meta-analysis: not done
Other
Atopiclair™ superior to vehicle for mild to moderate AE Adults andchildren 4
94-98 489 Mixed None
Education superior to no-education for moderate to severe
AE
Mainly
children 7
99-105 1076 Mixed Ersser 2014
106
Number of included studies:10
Meta-analysis: not done
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Table 2: Treatments with reasonable evidence of no benefit for AE patients332
333
334
335
336
337
Evidence of no benefit: at least one good quality RCT or several less well reported RCTs which consistently failed to show a convincing benefit on overall
disease activity. We defined a ‘good quality’ trial as well designed and well reported, and large enough to exclude a clinically useful benefit or several trials
with no evidence of benefit to give confidence in there being no clinically relevant benefit, despite less clear reporting
Intervention and severity of AE Population Trials (n) Participants(n)
Risk of
bias Systematic Review(s)
Twice daily versus once daily topical
corticosteroids
Adults and children 334,107,108 617 Mostly
unclear
Green (2005)109
Number of included studies: 10
Meta-analysis: not preformed (heterogeneity)
Antibiotic-containing corticosteroids
versus corticosteroids alone for mild
to severe non-infected AE
Mainly unspecified 5110-114 352 Mostly
unclear
Bath-Hextall (2010) 115
Number of included studies: 2
Meta-analysis: RR 0.52, 95% CI 0.23 to 1.16
Probiotics for treating AE versus
placebo
Mainly children 20116-135 1513 Mostly
unclear
Boyle (2009) 136
Number of included studies: 5
Meta-analysis: mean difference -0.90, 95% CI -
2.84 to 1.04
Dietary supplements rich in linoleic
acid (evening primrose oil and borage
oil) versus placebo
Mainly adults 23137-158 1448 Mostly
unclear
Bamford (2013) 159
Number of included studies: evening primrose
oil (7 trials)
Meta-analysis for Evening Primrose Oil mean
difference -2.22, 95% CI -10.48 to 6.04.
Number of included studies: borage oil (8 trials)
Meta-analysis for borage oil: not preformed
(heterogeneity)
Protease inhibitor SRD441 versus
vehicle in for mild to moderate AE
Adults 1160 93 Mostly low SR not applicable
Emollient with furfuryl palmitate
versus emollient alone for mild to
moderate AE
Children 1161 117 Low SR not applicable
Ion exchange water softening devices
versus no water softening for
moderate to severe AE
Children 1162 336 Low SR not applicable
Cipamfylline cream versus vehicle Adults 1163 103 Mostly low SR not applicable
Mycobacterium vaccae vaccine
versus no vaccine for moderate to
severe AE
Mainly children 4164-167 372 Low None
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Intervention Number
of trials
Number of
participants
Emollients 20168-186 1664
Dietary interventions including prebiotics, dietary restrictions, and synbiotics 13187-199 711
Non-pharmacological interventions, including: specialised clothing (silk or synthetic fibres with or without antibiotics);
environmental interventions (house dust mite reduction, desensitisation); staying in a different climate; different approaches
to organisation of care such as additional visits to the doctors or nurse led clinics; support groups; e-health management;
psychological therapies (stress reduction or habit reversal techniques); balneotherapy (salt baths); biofeedback
33200-232 2447
Oral antibiotics for clinically infected or uninfected AE 3233-235 125
Topical corticosteroids combined with topical antibiotics for infected AE 2110,236 660
Wet wraps in addition to topical corticosteroids 5237-241 153
Antiseptic and non-antiseptic bath additives 4242-245 97
Systemic and topical antifungals 4246-249 202
Topical treatments including: topical vitamin B12; topical coal tar; camellia oil; SRD441 (protease inhibitor); WBI-1001 (an
inhibitor of T cell inflammatory cytokine secretion); hippophe rhamnoides; black seed oil; pill mask; rosmarinic acid;
vitreoscilla filiformis; shale oil; miltefosine; opiate receptor antagonist; carbohydrate derived fulvic acid; raffinose; farnesol
and xylitol, bacterial antigens; camomile extract; heparin and levomenol; 15(R/S)-Methyl-lipoxin A4, N-acetyl-l-
hydroxyproline; nalmefene hydrochloride monohydrate (SRD174)
27250-276 1340
Systemic treatments including: oral prednisolone; methotrexate; mycophenolate mofetil; biological therapies (omalizumab;
mepolizumab); intravenous immunoglobulin; montelukast
22277-298 900
Oral antihistamines 29297,299-
326
4201
Other less commonly used interventions including: oral pimecrolimus; oral naltrexone; autologous blood therapy;
tandospirone citrate; full spectrum light therapy; excimer laser; nitrazepam; theophylline; topical salbutamol; papaverine and
suplatast tosilate
14327-338 481
Complementary therapies including: Chinese Herbal treatment; hypnotherapy; massage therapy; aromatherapy; acupuncture;
acupressure; and other herbal treatments
17339-354 604
Table 3: Treatments which require more research338
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Table 1: Treatments with reasonable evidence of benefit for eczema patients
Intervention and severity of AE Population Trials (n) Participants (n) Risk of bias Systematic Review(s)
Topical Corticosteroids
Corticosteroids (various strengths) are superior to vehicle for AE of all severities Adults andchildren 23
1-22 3857 Mostlyunclear None
Topical Calcineurin Inhibitors
Pimecrolimus (1%) is superior to vehicle for mild to moderate AE Mainlychildren
1623-37 3149 Mostly
unclear
Chen (2011)38
Number of included studies: 6
Meta-analysis: OR 3.21, 95% CI 2.48 to 4.14
Tacrolimus (0.03, 0.1, 0.3%) is superior to vehicle for moderate to severe AE Adults andchildren 9
39-45 2089 Mostlyunclear
Chen (2011)38
Number of included studies: 4
Meta-analysis: OR 4.56, 95% CI 2.80 to 7.44
Tacrolimus (0.03, 0.1%) is superior to hydrocortisone acetate (1%) for moderate-to severe AE Children 246,47 1184 Unclear
Ashcroft (2005)48
Number of included studies: 2
Meta-analysis: unsure
Tacrolimus (0.1%) superior to fluticasone propionate ointment (0.005%) for moderate to severe facial AE Adults 149 568 Mostlyunclear Not applicable
Tacrolimus (0.1, 0.03%) is superior to pimecrolimus (1%) for AE of all severities Adults andchildren 5
50-52 1243 Mostly low
Martins (2015)53
Number of included studies: 3
Meta-analysis: RR 1.80, 95% CI 1.35 to 2.42
Proactive (maintenance) topical therapy for preventing flares
Corticosteroids applied twice a week are superior to vehicle for moderate to severe AE Adults andchildren 4
54-57 929 Mostlyunclear
Schmitt (2011)58
Number of included studies: 4
Meta-analysis: RR 0.46, 95% CI 0.38-0.55
Tacrolimus (0.1, 0.03%) applied twice a week is superior to vehicle for mild to severe AE Adults andchildren 4
59-62 741 Mostlyunclear
Schmitt (2011)58
Number of included studies: 3
Meta-analysis: RR 0.78, 95% CI 0.60-1.00
Pimecrolimus (1%) applied twice a week is superior to vehicle for AE of all severities Mainlychildren 2
24,63 251 Mostly low None
Systemic Therapies
Ciclosporin superior to placebo for severe AE Adults 464-67 113 Mostlyunclear
Schmitt 200768
Number of included studies: (12)
Meta-analysis: (included non-RCTs)
Azathioprine superior to placebo for moderate to severe AE Adults 269,70 100 Mostly low
Schram 201171
Number of included studies:
Meta-analysis:
Ultra-violet Light Therapy
NB-UVB superior to placebo (visible light) for moderate to severe AE Adults 272,73 116 Mostlyunclear
Gambichler 200574
Number of included studies:
Meta-analysis:
Dogra 2015
Other
Atopiclair™ superior to vehicle for mild to moderate AE Adults andchildren 4
75-79 489 Mixed None
Education superior to no-education for moderate to severe AE Mainlychildren 7
80-86 1076 Mixed
Pickett (2015) 87
Number of included studies:7
Meta-analysis: not performed (heterogeneity)
Ersser 2014 88
Number of studies:10
Meta-analysis: not performed (lack of data)
Table 2: Treatments with reasonable evidence of no benefit for eczema patients
Evidence of no benefit: at least one good quality RCT or several less well reported RCTs which consistently failed to show a convincing benefit on overall disease activity. We defined a ‘good quality’ trial as well designed and well
reported, and large enough to exclude a clinically useful benefit or several trials with no evidence of benefit to give confidence in there being no clinically relevant benefit, despite less clear reporting
Intervention No. of
Trials
No. of
Participants
Risk of bias Population
applied to
Severity of AE Relevant systematic reviews
Twice daily versus once daily topical corticosteroids 314,89,90 617 Mainly unclear risk of
bias
Adults and
children
Mainly
unspecified
Green (2005)91
Number of included studies: 10
Meta-analysis: not preformed (heterogeneity)
Topical corticosteroids in combination with antibiotics for AE that is not
clinically infected versus topical corticosteroid only
592-96 352 Mainly low or unclear
risk of bias
Mainly unspecified Mild to severe Bath-Hextall (2010) 97
Number of included studies: 2
Meta-analysis: RR 0.52, 95% CI 0.23 to 1.16
Probiotics for treating established AE versus placebo 2098-117 1513 Mainly unclear risk of
bias
Mainly children Unspecified Boyle (2009) 118
Number of included studies: 5
Meta-analysis: mean difference -0.90, 95% CI -2.84 to
1.04
Dietary supplements rich in linoleic acid such as evening primrose oil and
borage oil versus placebo
23119-140 1448 Mainly unclear risk of
bias
Mainly adults Unspecified Bamford (2013) 141
Number of included studies: evening primrose oil (7
trials)
Meta-analysis for Evening Primrose Oil mean
difference -2.22, 95% CI -10.48 to 6.04.
Number of included studies: borage oil (8 trials)
Meta-analysis for borage oil: not preformed
(heterogeneity)
Other topical treatment: protease inhibitor SRD441 versus vehicle in
adults with mild to moderate AE
1142 93 Mainly low risk of bias Adults Mild to moderate SR not applicable
Other topical treatment: emollient with furfuryl palmitate versus
emollient only
1143 117 Low risk of bias Children Unspecified SR not applicable
Ion exchange water softening devices versus no water softening 1144 336 Low risk of bias Children Moderate to
severe
SR not applicable
Other topical treatment: cipamfylline cream versus vehicle 1145 103 Mainly low risk of bias Adults Unspecified SR not applicable
Mycobacterium vaccae vaccine versus no vaccine 4146-149 372 Low risk of bias Mainly children Moderate to
severe
None
Table 3: Treatments which require more research
Intervention Number of
trials
Number of
participants
Emollients 20150-168 1664
Dietary interventions including prebiotics, dietary restrictions, and synbiotics 13169-181 711
Non-pharmacological interventions, including: specialised clothing (silk or synthetic fibres with or without antibiotics); environmental interventions (house dust mite reduction, desensitisation); staying
in a different climate; different approaches to organisation of care such as additional visits to the doctors or nurse led clinics; support groups; e-health management; psychological therapies (stress
reduction or habit reversal techniques); balneotherapy (salt baths); biofeedback
33182-214 2447
Oral antibiotics for clinically infected or uninfected AE 3215-217 125
Topical corticosteroids combined with topical antibiotics for infected AE 292,218 660
Wet wraps in addition to topical corticosteroids 5219-223 153
Antiseptic bath additives 3224-226 66
Systemic and topical antifungals 4227-230 202
Topical treatments including: topical vitamin B12; topical coal tar; camellia oil; SRD441 (protease inhibitor); WBI-1001 (an inhibitor of T cell inflammatory cytokine secretion); hippophe rhamnoides;
black seed oil; pill mask; rosmarinic acid; vitreoscilla filiformis; shale oil; miltefosine; opiate receptor antagonist; carbohydrate derived fulvic acid; raffinose; farnesol and xylitol, bacterial antigens;
camomile extract; heparin and levomenol; 15(R/S)-Methyl-lipoxin A4, N-acetyl-l-hydroxyproline; nalmefene hydrochloride monohydrate (SRD174)
27231-257 1340
Systemic treatments including: oral prednisolone; methotrexate; mycophenolate mofetil; biological therapies (omalizumab; mepolizumab); intravenous immunoglobulin; montelukast 22258-279 900
Oral antihistamines 29278,280-307 4201
Other less commonly used interventions including: oral pimecrolimus; oral naltrexone; autologous blood therapy; tandospirone citrate; full spectrum light therapy; excimer laser; nitrazepam;
theophylline; topical salbutamol; papaverine and suplatast tosilate
14308-319 481
Complementary therapies including: Chinese Herbal treatment; hypnotherapy; massage therapy; aromatherapy; acupuncture; acupressure; and other herbal treatments 17320-335 604
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Supplementary Table 1: Search strategy (see separate file)
Supplementary Table 2: Criteria used for discussing the risk of bias in the summaries of treatment categories
Risk of bias description in the chapter summaries
Collective risk of bias descriptions for summary statements Basis for description
Overall low risk of bias Method of generating the randomisation sequence, concealment of the allocation sequence, and blinding were assessed as low risk for all the trials summarised
Overall unclear risk of bias Method of generating the randomisation sequence, concealment of the allocation sequence, and blinding were assessed as unclear risk for all the trials summarised
Overall high risk of bias Method of generating the randomisation sequence, concealment of the allocation sequence, and blinding were assessed as high risk for all the trials summarised
Mostly low risk of bias A clear majority of the method of generating the randomisation sequence, concealment of the allocation sequence, and blinding
Mostly unclear risk of bias A clear majority of the method of generating the randomisation sequence, concealment of the allocation sequence, and blinding
Mostly high risk of bias A clear majority of the method of generating the randomisation sequence, concealment of the allocation sequence, and blinding
A high risk of bias for (randomisation/allocation concealment/blinding) One of method of generating the randomisation sequence, concealment of the allocation sequence, and blinding assessed as high for all, or in the case of
many trials, almost all trials summarised.
A mixed risk of bias The assessments were a fairly even distribution of risk of bias for method of generating the randomisation sequence, concealment of the allocation sequence, and blinding for the trials summarised.
Supplementary Table 1: Criteria used for discussing the risk of bias in the summaries of treatment categories
Risk of bias description in the chapter summaries
Collective risk of bias
descriptions for summary
statements
Basis for description
Low
Method of generating the randomisation sequence, concealment of the
allocation sequence, and blinding were assessed as being low risk for all the
trials summarised
Unclear
Method of generating the randomisation sequence, concealment of the
allocation sequence, and blinding were assessed as being unclear risk for all
the trials summarised
High
Method of generating the randomisation sequence, concealment of the
allocation sequence, and blinding were assessed as being high risk for all the
trials summarised
Mostly low
A clear majority of the method of generating the randomisation sequence,
concealment of the allocation sequence, and blinding were assessed as being
low risk for the trials summarised
Mostly unclear
A clear majority of the method of generating the randomisation sequence,
concealment of the allocation sequence, and blinding were assessed as being
unclear risk for the trials summarised
Mostly high
A clear majority of the method of generating the randomisation sequence,
concealment of the allocation sequence, and blinding were assessed as being
high risk for the trials summarised
Mixed
A fairly even distribution of risk of bias for method of generating the
randomisation sequence, concealment of the allocation sequence, and
blinding for the trials summarised.
Supplementary ﬁgure 2: Summary of included interventions
Supplementary Figure 1: Search strategy used to identify trials
MEDLINE (Ovid) Cochrane Collaboration Highly sensitive search string
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp Dermatitis, Atopic/
15. atopic dermatitis.mp.
16. atopic eczema.mp.
17. exp NEURODERMATITIS/
18. neurodermatitis.mp.
19. infantile eczema.mp.
20. childhood eczema.mp.
21. (besnier$ and prurigo).mp. [mp=title, abstract, subject headings,
heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
22. eczema.mp. or exp Eczema/
23. 21 or 17 or 20 or 15 or 14 or 22 or 18 or 16 or 19
24. 23 and 13
EMBASE search string (Ovid)
1. random$.mp.
2. factorial$.mp.
3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, drug
trade name, original title, device manufacturer, drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, drug
trade name, original title, device manufacturer, drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
